SOC FFPE KRAS testing results on primary tumor specimens were only available for 43 KRAS-MUT+ patients with MAF values < 1% at the hospital centers performing OncoBEAM testing (Fig. 1). The gene discussed is KRAS; the disease is neoplasm.